应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
NKTR 内克塔治疗
盘后交易 11-04 16:40:31 EST
1.33
+0.10
+8.13%
盘后
1.29
-0.04
-3.01%
16:29 EST
最高
1.47
最低
1.27
成交量
596.75万
今开
1.37
昨收
1.23
日振幅
16.67%
总市值
2.45亿
流通市值
2.06亿
总股本
1.84亿
成交额
818.54万
换手率
3.86%
流通股本
1.55亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
内克塔治疗盘中异动 早盘股价大涨14.23%报1.41美元
市场透视 · 11-04 22:31
内克塔治疗盘中异动 早盘股价大涨14.23%报1.41美元
美国研究综述-亚马逊、雪佛龙、万事达卡
Reuters · 11-04 15:23
美国研究综述-亚马逊、雪佛龙、万事达卡
Nektar Therapeutics 预计每股亏损 21 美分 - 财报前瞻
Reuters · 11-02 12:04
Nektar Therapeutics 预计每股亏损 21 美分 - 财报前瞻
内克塔治疗盘中异动 大幅上涨5.04%
市场透视 · 11-02
内克塔治疗盘中异动 大幅上涨5.04%
内克塔治疗盘中异动 大幅拉升5.30%
市场透视 · 10-29
内克塔治疗盘中异动 大幅拉升5.30%
内克塔治疗盘中异动 急速拉升5.07%
市场透视 · 10-18
内克塔治疗盘中异动 急速拉升5.07%
内克塔治疗盘中异动 股价大涨5.43%报1.36美元
市场透视 · 10-16
内克塔治疗盘中异动 股价大涨5.43%报1.36美元
内克塔治疗盘中异动 快速下挫5.15%
市场透视 · 10-14
内克塔治疗盘中异动 快速下挫5.15%
内克塔治疗盘中异动 临近收盘股价大涨5.04%报1.36美元
市场透视 · 10-12
内克塔治疗盘中异动 临近收盘股价大涨5.04%报1.36美元
内克塔治疗盘中异动 股价大涨5.30%报1.39美元
市场透视 · 10-07
内克塔治疗盘中异动 股价大涨5.30%报1.39美元
内克塔治疗盘中异动 大幅上涨5.38%报1.37美元
市场透视 · 10-05
内克塔治疗盘中异动 大幅上涨5.38%报1.37美元
内克塔治疗盘中异动 股价大涨5.00%
市场透视 · 10-03
内克塔治疗盘中异动 股价大涨5.00%
内克塔治疗盘中异动 早盘急速拉升5.13%报1.23美元
市场透视 · 09-30
内克塔治疗盘中异动 早盘急速拉升5.13%报1.23美元
内克塔治疗盘中异动 早盘快速上涨5.41%报1.17美元
市场透视 · 09-27
内克塔治疗盘中异动 早盘快速上涨5.41%报1.17美元
内克塔治疗盘中异动 快速跳水5.37%
市场透视 · 09-25
内克塔治疗盘中异动 快速跳水5.37%
内克塔治疗盘中异动 股价大跌5.00%
市场透视 · 09-23
内克塔治疗盘中异动 股价大跌5.00%
内克塔治疗盘中异动 快速跳水5.24%报1.26美元
自选股智能写手 · 08-20
内克塔治疗盘中异动 快速跳水5.24%报1.26美元
内克塔治疗盘中异动 急速拉升5.20%
自选股智能写手 · 08-20
内克塔治疗盘中异动 急速拉升5.20%
内克塔治疗2024财年第二财季实现净利润-52.36百万美元,同比减少2.43%
自选股智能写手 · 08-18
内克塔治疗2024财年第二财季实现净利润-52.36百万美元,同比减少2.43%
内克塔治疗盘中异动 临近收盘股价大涨5.04%
自选股智能写手 · 08-17
内克塔治疗盘中异动 临近收盘股价大涨5.04%
加载更多
公司概况
公司名称:
内克塔治疗
所属市场:
NASDAQ
上市日期:
--
主营业务:
Nektar Therapeutics于1990年在加州成立,并于1998年重新在特拉华州注册。这是临床阶段生物制药公司,其利用PEG修饰和先进的聚合物共轭技术平台开发一个管道的候选药物。这些平台是为了认识其作用机制确保新分子实体的发展。当前专用管道包括跨多个治疗领域包括肿瘤、疼痛、抗感染和免疫领域候选药物。研究和开发活动涉及两种小分子和生物药物的候选。公司通过使用专有先进聚合物共轭技术来修改药效基因创建新的分子实体的化学结构,从而来创建创新候选药物。司收入来源于与伙伴合作协议,它可以接收合同研究支付、根据临床进展和监管进展或净销售额获得里程碑付款、版税或生产收入。
发行价格:
--
{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"内克塔治疗","latestPrice":1.33,"timestamp":1730754000000,"preClose":1.23,"halted":0,"volume":5967450,"hourTrading":{"tag":"盘后","latestPrice":1.29,"preClose":1.33,"latestTime":"16:29 EST","volume":13509,"amount":18039.420117899997,"timestamp":1730755790497},"delay":0,"floatShares":154659344,"shares":184079479,"eps":-0.902275,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.1,"latestTime":"11-04 16:40:31 EST","open":1.37,"high":1.47,"low":1.265,"amount":8185430.025765,"amplitude":0.166667,"askPrice":1.36,"askSize":200,"bidPrice":1.29,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.902275,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1730768400000},"adr":0,"adjPreClose":1.23,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":1.38,"preClose":1.23,"latestTime":"09:29 EST","volume":283155,"amount":383523.0557115,"timestamp":1730730597042},"postHourTrading":{"tag":"盘后","latestPrice":1.29,"preClose":1.33,"latestTime":"16:29 EST","volume":13509,"amount":18039.420117899997,"timestamp":1730755790497},"volumeRatio":4.688456,"impliedVol":0.921,"impliedVolPercentile":0.2191},"requestUrl":"/m/hq/s/NKTR","defaultTab":"news","newsList":[{"id":"2480819885","title":"内克塔治疗盘中异动 早盘股价大涨14.23%报1.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480819885","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480819885?lang=zh_cn&edition=full","pubTime":"2024-11-04 22:31","pubTimestamp":1730730686,"startTime":"0","endTime":"0","summary":"北京时间2024年11月04日22时31分,内克塔治疗股票出现波动,股价快速上涨14.23%。截至发稿,该股报1.41美元/股,成交量63.985万股,换手率0.35%,振幅6.50%。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.14%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110422312695bdc9a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110422312695bdc9a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2480324011","title":"美国研究综述-亚马逊、雪佛龙、万事达卡","url":"https://stock-news.laohu8.com/highlight/detail?id=2480324011","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480324011?lang=zh_cn&edition=full","pubTime":"2024-11-04 15:23","pubTimestamp":1730705034,"startTime":"0","endTime":"0","summary":" 路透11月4日 - 华尔街证券分析师周一调整了对亚马逊、雪佛龙和万事达卡等几家美国上市公司的评级和目标价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUBI","BTSG","EAT","LU0096362180.USD","LU0122376428.USD","CVCO","ARCB","IE00BMPRXR70.SGD","VERX","USCB","KLC","CVX","MD","WING","IE00BFXG0V08.USD","ARES","MSGS","BK4139","MRNA","AMZN","LU0640476718.USD","TFX","VECO","BK4527","GILD","LU0211327993.USD","OWL","MA","CAR","LU0077335932.USD","CAH","LU2125154778.USD","SITC","NKTR","LU2087621335.USD","RGA","BK4220","WAT","LU2361044865.SGD","VKTX","ITCI","MNST","DHI","LU0240878834.USD","SFM","COP","LU0079474960.USD","V","TROW","BXP"],"gpt_icon":1},{"id":"2480818268","title":"Nektar Therapeutics 预计每股亏损 21 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2480818268","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480818268?lang=zh_cn&edition=full","pubTime":"2024-11-02 12:04","pubTimestamp":1730520288,"startTime":"0","endTime":"0","summary":" * Nektar Therapeutics 将于11月7日公布截至2024年9月30日的财报,预计季度收入将出现下降。* 根据LSEG的数据,6位分析师的平均预期显示,这家总部位于加利福尼亚州旧金山的公司的营收将从去年同期的2414万美元下降24.3%,至1828.4万美元。* LSEG 分析师对 Nektar Therapeutics 的平均预期是每股亏损 21 美分。* 华尔街对 Nektar Therapeutics 的 12 个月目标价中位数为 2.65 美元,高于其上次收盘价 1.23 美元。11月2日 - 以往季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NKTR"],"gpt_icon":0},{"id":"2480922834","title":"内克塔治疗盘中异动 大幅上涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480922834","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480922834?lang=zh_cn&edition=full","pubTime":"2024-11-02 00:41","pubTimestamp":1730479312,"startTime":"0","endTime":"0","summary":"北京时间2024年11月02日00时41分,内克塔治疗股票出现波动,股价快速拉升5.04%。截至发稿,该股报1.25美元/股,成交量29.1971万股,换手率0.16%,振幅2.69%。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.75%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。该公司拥有肿瘤学、免疫学和病毒学研究药物的全资研发管线,以及一系列获批的合作药物。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241102004152ab93b3d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241102004152ab93b3d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2479794434","title":"内克塔治疗盘中异动 大幅拉升5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479794434","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479794434?lang=zh_cn&edition=full","pubTime":"2024-10-29 00:49","pubTimestamp":1730134162,"startTime":"0","endTime":"0","summary":"北京时间2024年10月29日00时49分,内克塔治疗股票出现异动,股价快速拉升5.30%。截至发稿,该股报1.39美元/股,成交量36.309万股,换手率0.20%,振幅4.17%。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.24%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。该公司拥有肿瘤学、免疫学和病毒学研究药物的全资研发管线,以及一系列获批的合作药物。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029004923971a2b6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029004923971a2b6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2476101975","title":"内克塔治疗盘中异动 急速拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2476101975","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476101975?lang=zh_cn&edition=full","pubTime":"2024-10-18 00:12","pubTimestamp":1729181538,"startTime":"0","endTime":"0","summary":"北京时间2024年10月18日00时12分,内克塔治疗股票出现波动,股价大幅拉升5.07%。截至发稿,该股报1.45美元/股,成交量95.2936万股,换手率0.52%,振幅5.80%。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.73%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018001218ab6ade21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018001218ab6ade21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2475197239","title":"内克塔治疗盘中异动 股价大涨5.43%报1.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2475197239","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475197239?lang=zh_cn&edition=full","pubTime":"2024-10-16 22:47","pubTimestamp":1729090023,"startTime":"0","endTime":"0","summary":"北京时间2024年10月16日22时47分,内克塔治疗股票出现波动,股价大幅拉升5.43%。截至发稿,该股报1.36美元/股,成交量17.6407万股,换手率0.10%,振幅5.43%。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.40%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101622470398e3cce5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101622470398e3cce5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2475398756","title":"内克塔治疗盘中异动 快速下挫5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475398756","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475398756?lang=zh_cn&edition=full","pubTime":"2024-10-14 22:12","pubTimestamp":1728915175,"startTime":"0","endTime":"0","summary":"北京时间2024年10月14日22时12分,内克塔治疗股票出现异动,股价快速下跌5.15%。机构评级方面,在所有6家参与评级的机构中,17%的券商给予买入建议,67%的券商给予持有建议,16%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.02%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101422125598e3c4ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101422125598e3c4ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2474402044","title":"内克塔治疗盘中异动 临近收盘股价大涨5.04%报1.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474402044","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474402044?lang=zh_cn&edition=full","pubTime":"2024-10-12 03:56","pubTimestamp":1728676564,"startTime":"0","endTime":"0","summary":"北京时间2024年10月12日03时56分,内克塔治疗股票出现异动,股价快速上涨5.04%。截至发稿,该股报1.36美元/股,成交量105.443万股,换手率0.57%,振幅6.20%。内克塔治疗股票所在的生物技术行业中,整体涨幅为1.28%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241012035605a1e00b97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241012035605a1e00b97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2473105922","title":"内克塔治疗盘中异动 股价大涨5.30%报1.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2473105922","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473105922?lang=zh_cn&edition=full","pubTime":"2024-10-07 21:31","pubTimestamp":1728307860,"startTime":"0","endTime":"0","summary":"北京时间2024年10月07日21时31分,内克塔治疗股票出现波动,股价急速拉升5.30%。截至发稿,该股报1.39美元/股,成交量1.5728万股,换手率0.01%,振幅0.00%。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.00%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100721310198e3ad64&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100721310198e3ad64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2473828999","title":"内克塔治疗盘中异动 大幅上涨5.38%报1.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2473828999","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473828999?lang=zh_cn&edition=full","pubTime":"2024-10-05 03:00","pubTimestamp":1728068410,"startTime":"0","endTime":"0","summary":"北京时间2024年10月05日03时00分,内克塔治疗股票出现波动,股价快速拉升5.38%。截至发稿,该股报1.37美元/股,成交量35.8533万股,换手率0.19%,振幅5.38%。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.10%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100503001198e3aa71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100503001198e3aa71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2472357717","title":"内克塔治疗盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2472357717","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472357717?lang=zh_cn&edition=full","pubTime":"2024-10-03 02:11","pubTimestamp":1727892711,"startTime":"0","endTime":"0","summary":"北京时间2024年10月03日02时11分,内克塔治疗股票出现异动,股价急速上涨5.00%。截至发稿,该股报1.37美元/股,成交量171.166万股,换手率0.93%,振幅7.69%。内克塔治疗股票所在的生物技术行业中,整体跌幅为1.17%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。该公司拥有肿瘤学、免疫学和病毒学研究药物的全资研发管线,以及一系列获批的合作药物。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241003021151ab677bcd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241003021151ab677bcd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2471573383","title":"内克塔治疗盘中异动 早盘急速拉升5.13%报1.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2471573383","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471573383?lang=zh_cn&edition=full","pubTime":"2024-09-30 21:31","pubTimestamp":1727703104,"startTime":"0","endTime":"0","summary":"北京时间2024年09月30日21时31分,内克塔治疗股票出现异动,股价快速拉升5.13%。截至发稿,该股报1.23美元/股,成交量3.2384万股,换手率0.02%,振幅0.85%。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.31%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。该公司拥有肿瘤学、免疫学和病毒学研究药物的全资研发管线,以及一系列获批的合作药物。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930213144a1ddb416&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240930213144a1ddb416&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2470089885","title":"内克塔治疗盘中异动 早盘快速上涨5.41%报1.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470089885","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470089885?lang=zh_cn&edition=full","pubTime":"2024-09-27 21:39","pubTimestamp":1727444369,"startTime":"0","endTime":"0","summary":"北京时间2024年09月27日21时39分,内克塔治疗股票出现波动,股价快速上涨5.41%。截至发稿,该股报1.17美元/股,成交量12.8875万股,换手率0.07%,振幅2.70%。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.14%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。该公司拥有肿瘤学、免疫学和病毒学研究药物的全资研发管线,以及一系列获批的合作药物。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240927213929a1dd110a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240927213929a1dd110a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2470378264","title":"内克塔治疗盘中异动 快速跳水5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2470378264","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470378264?lang=zh_cn&edition=full","pubTime":"2024-09-25 23:18","pubTimestamp":1727277524,"startTime":"0","endTime":"0","summary":"北京时间2024年09月25日23时18分,内克塔治疗股票出现波动,股价急速跳水5.37%。截至发稿,该股报1.15美元/股,成交量29.1151万股,换手率0.16%,振幅4.55%。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.46%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。该公司拥有肿瘤学、免疫学和病毒学研究药物的全资研发管线,以及一系列获批的合作药物。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409252318449719ca23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409252318449719ca23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2469814852","title":"内克塔治疗盘中异动 股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2469814852","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469814852?lang=zh_cn&edition=full","pubTime":"2024-09-23 22:10","pubTimestamp":1727100650,"startTime":"0","endTime":"0","summary":"北京时间2024年09月23日22时10分,内克塔治疗股票出现波动,股价大幅下挫5.00%。截至发稿,该股报1.24美元/股,成交量11.4491万股,换手率0.06%,振幅5.00%。机构评级方面,在所有5家参与评级的机构中,80%的券商给予持有建议,20%的券商给予卖出建议,无券商给予买入建议。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.84%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092322105098e38734&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024092322105098e38734&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2460004575","title":"内克塔治疗盘中异动 快速跳水5.24%报1.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460004575","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460004575?lang=zh_cn&edition=full","pubTime":"2024-08-20 21:47","pubTimestamp":1724161629,"startTime":"0","endTime":"0","summary":"北京时间2024年08月20日21时47分,内克塔治疗股票出现异动,股价快速跳水5.24%。截至发稿,该股报1.26美元/股,成交量7.4381万股,换手率0.04%,振幅5.64%。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.87%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。该公司拥有肿瘤学、免疫学和病毒学研究药物的全资研发管线,以及一系列获批的合作药物。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082021470998e35871&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082021470998e35871&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2460576430","title":"内克塔治疗盘中异动 急速拉升5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460576430","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460576430?lang=zh_cn&edition=full","pubTime":"2024-08-20 01:36","pubTimestamp":1724089009,"startTime":"0","endTime":"0","summary":"北京时间2024年08月20日01时36分,内克塔治疗股票出现波动,股价快速上涨5.20%。截至发稿,该股报1.32美元/股,成交量60.2368万股,换手率0.33%,振幅6.00%。机构评级方面,在所有5家参与评级的机构中,80%的券商给予持有建议,20%的券商给予卖出建议,无券商给予买入建议。内克塔治疗股票所在的生物技术行业中,整体涨幅为0.89%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820013649ab5e6fbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240820013649ab5e6fbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2460739338","title":"内克塔治疗2024财年第二财季实现净利润-52.36百万美元,同比减少2.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460739338","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460739338?lang=zh_cn&edition=full","pubTime":"2024-08-18 00:03","pubTimestamp":1723910631,"startTime":"0","endTime":"0","summary":"8月18日,内克塔治疗公布财报,公告显示公司2024财年第二财季净利润为-52.36百万美元,同比减少2.43%;其中营业收入为23.49百万美元,同比增加14.59%,每股基本收益为-0.25美元。从资产负债表来看,内克塔治疗总负债2.64亿美元,其中短期债务21.34百万美元,资产负债比为1.30,流动比率为0.06。机构评级:截至2024年8月18日,当前有2家机构对内克塔治疗目标价做出预测,其中目标均价为1.65美元,其中最低目标价为1.30美元,最高目标价为2.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800060395a16749&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800060395a16749&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR"],"gpt_icon":0},{"id":"2460041226","title":"内克塔治疗盘中异动 临近收盘股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460041226","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460041226?lang=zh_cn&edition=full","pubTime":"2024-08-17 03:36","pubTimestamp":1723836977,"startTime":"0","endTime":"0","summary":"北京时间2024年08月17日03时36分,内克塔治疗股票出现异动,股价大幅拉升5.04%。截至发稿,该股报1.25美元/股,成交量44.4157万股,换手率0.24%,振幅5.88%。机构评级方面,在所有5家参与评级的机构中,80%的券商给予持有建议,20%的券商给予卖出建议,无券商给予买入建议。内克塔治疗股票所在的生物技术行业中,整体跌幅为0.25%。内克塔治疗公司简介:Nektar Therapeutics是一家生物制药公司。在病毒学方面,该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081703361798e35372&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081703361798e35372&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.0682},{"period":"1month","weight":-0.0752},{"period":"3month","weight":0.025},{"period":"6month","weight":-0.2166},{"period":"1year","weight":1.4894},{"period":"ytd","weight":1.177}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":0.0038},{"period":"3month","weight":0.0716},{"period":"6month","weight":0.1169},{"period":"1year","weight":0.3257},{"period":"ytd","weight":0.2014}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nektar Therapeutics于1990年在加州成立,并于1998年重新在特拉华州注册。这是临床阶段生物制药公司,其利用PEG修饰和先进的聚合物共轭技术平台开发一个管道的候选药物。这些平台是为了认识其作用机制确保新分子实体的发展。当前专用管道包括跨多个治疗领域包括肿瘤、疼痛、抗感染和免疫领域候选药物。研究和开发活动涉及两种小分子和生物药物的候选。公司通过使用专有先进聚合物共轭技术来修改药效基因创建新的分子实体的化学结构,从而来创建创新候选药物。司收入来源于与伙伴合作协议,它可以接收合同研究支付、根据临床进展和监管进展或净销售额获得里程碑付款、版税或生产收入。","yearOnYearQuotes":[{"month":1,"riseRate":0.566667,"avgChangeRate":0.047978},{"month":2,"riseRate":0.5,"avgChangeRate":0.00268},{"month":3,"riseRate":0.4,"avgChangeRate":0.004229},{"month":4,"riseRate":0.433333,"avgChangeRate":0.006304},{"month":5,"riseRate":0.366667,"avgChangeRate":0.006185},{"month":6,"riseRate":0.387097,"avgChangeRate":-0.018715},{"month":7,"riseRate":0.451613,"avgChangeRate":-0.014995},{"month":8,"riseRate":0.451613,"avgChangeRate":0.034164},{"month":9,"riseRate":0.483871,"avgChangeRate":0.014638},{"month":10,"riseRate":0.354839,"avgChangeRate":-0.028591},{"month":11,"riseRate":0.709677,"avgChangeRate":0.092239},{"month":12,"riseRate":0.633333,"avgChangeRate":0.03444}],"exchange":"NASDAQ","name":"内克塔治疗","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"内克塔治疗,NKTR,内克塔治疗股票,内克塔治疗股票老虎,内克塔治疗股票老虎国际,内克塔治疗行情,内克塔治疗股票行情,内克塔治疗股价,内克塔治疗股市,内克塔治疗股票价格,内克塔治疗股票交易,内克塔治疗股票购买,内克塔治疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}